Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 175,000 | 421,000 | 202,510 | 176,306 | 127,055 |
| Marketable Securities | 238,000 | 259,000 | 222,738 | 311,279 | 367,385 |
| Receivables | 121,000 | 158,000 | 112,543 | 124,464 | 98,839 |
| Inventories | 55,000 | 52,000 | 52,200 | 46,498 | 46,031 |
| TOTAL | $657,000 | $951,000 | $643,206 | $719,788 | $699,155 |
| Non-Current Assets | |||||
| PPE Net | 239,000 | 244,000 | 249,961 | 255,763 | 260,906 |
| Investments And Advances | 121,000 | 57,000 | 22,067 | 51,454 | 68,563 |
| Intangibles | 218,000 | 220,000 | 217,349 | 219,139 | 220,930 |
| Other Non-Current Assets | 61,000 | 60,000 | 57,862 | 60,121 | 62,373 |
| TOTAL | $639,000 | $581,000 | $547,239 | $586,477 | $612,772 |
| Total Assets | $1,296,000 | $1,532,000 | $1,190,445 | $1,306,265 | $1,311,927 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 42,000 | 31,000 | 40,573 | 34,242 | 47,450 |
| Accrued Expenses | 194,000 | 265,000 | 220,526 | 180,792 | 173,007 |
| Other current liabilities | 89,000 | 88,000 | 66,781 | 66,444 | 60,724 |
| TOTAL | $325,000 | $384,000 | $340,022 | $293,244 | $291,668 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,177,000 | 1,198,000 | 811,206 | 831,677 | 845,955 |
| TOTAL | $1,207,000 | $1,228,000 | $841,264 | $861,735 | $876,013 |
| Total Liabilities | $1,532,000 | $1,612,000 | $1,181,286 | $1,154,979 | $1,167,681 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 98,489 | 96,630 | 96,478 | 96,372 | 94,542 |
| Common Shares | N/A | N/A | 96 | 96 | 94 |
| Retained earnings | -4,717,000 | -4,532,000 | -4,403,288 | -4,222,875 | -4,107,924 |
| Other shareholders' equity | 10,000 | 9,000 | 8,820 | 7,732 | 7,659 |
| TOTAL | $-236,000 | $-80,000 | $9,159 | $151,286 | $144,246 |
| Total Liabilities And Equity | $1,296,000 | $1,532,000 | $1,190,445 | $1,306,265 | $1,311,927 |